Total Payments
$2.1M
2024 Payments
$255,559
Companies
30
Transactions
1,647
Medicare Patients
146
Medicare Billing
$9,004
Payment Breakdown by Category
Other$1.3M (59.8%)
Consulting$569,314 (27.0%)
Travel$245,504 (11.6%)
Food & Beverage$30,226 (1.4%)
Research$3,000 (0.1%)
Education$318.04 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 478 | 54.8% |
| Consulting Fee | $569,314 | 202 | 27.0% |
| Travel and Lodging | $245,504 | 464 | 11.6% |
| Honoraria | $95,627 | 31 | 4.5% |
| Food and Beverage | $30,226 | 462 | 1.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,585 | 1 | 0.5% |
| Unspecified | $3,000 | 1 | 0.1% |
| Education | $318.04 | 8 | 0.0% |
Payments by Type
General
$2.1M
1,646 transactions
Research
$3,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $425,365 | 260 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $257,925 | 221 | $0 (2024) |
| GlaxoSmithKline, LLC. | $178,942 | 57 | $0 (2024) |
| UCB, Inc. | $164,977 | 169 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $150,826 | 146 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $134,990 | 92 | $0 (2021) |
| Genentech USA, Inc. | $124,519 | 85 | $0 (2020) |
| Amgen Inc. | $117,356 | 120 | $0 (2024) |
| ABBVIE INC. | $103,544 | 94 | $0 (2024) |
| Horizon Therapeutics plc | $80,730 | 51 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $255,559 | 171 | GENZYME CORPORATION ($111,988) |
| 2023 | $243,889 | 184 | AstraZeneca Pharmaceuticals LP ($76,217) |
| 2022 | $316,455 | 245 | GENZYME CORPORATION ($94,571) |
| 2021 | $213,188 | 148 | AstraZeneca Pharmaceuticals LP ($54,105) |
| 2020 | $244,708 | 150 | GENZYME CORPORATION ($69,748) |
| 2019 | $335,503 | 286 | Horizon Therapeutics plc ($70,546) |
| 2018 | $266,766 | 249 | Novartis Pharmaceuticals Corporation ($59,525) |
| 2017 | $235,219 | 214 | E.R. Squibb & Sons, L.L.C. ($57,251) |
All Payment Transactions
1,647 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 12/21/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 12/20/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Consulting Fee | Cash or cash equivalent | $2,734.00 | General |
| Category: Rheumatology | ||||||
| 12/14/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $3,262.50 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,475.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $115.04 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $77.99 | General |
| Category: Immunology | ||||||
| 12/07/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,113.00 | General |
| Category: Rheumatology | ||||||
| 12/07/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | In-kind items and services | $1,109.03 | General |
| Category: Rheumatology | ||||||
| 12/07/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | In-kind items and services | $356.20 | General |
| Category: Rheumatology | ||||||
| 12/07/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Travel and Lodging | In-kind items and services | $151.00 | General |
| Category: Rheumatology | ||||||
| 12/05/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $81.96 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $1,420.00 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $1,162.51 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $259.28 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $121.34 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $41.74 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $30.87 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis | Kiniksa Pharmaceuticals, Ltd. | $3,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 33 | 39 | $12,459 | $2,052 |
| 2022 | 2 | 39 | 49 | $14,595 | $2,729 |
| 2021 | 2 | 36 | 43 | $12,806 | $2,329 |
| 2020 | 2 | 38 | 44 | $13,262 | $1,894 |
Total Patients
146
Total Services
175
Medicare Billing
$9,004
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 20 | 26 | $7,072 | $1,079 | 15.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 13 | $5,387 | $972.79 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 16 | 20 | $7,488 | $1,468 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 23 | 29 | $7,107 | $1,261 | 17.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 25 | $5,979 | $1,227 | 20.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 18 | $6,827 | $1,102 | 16.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 24 | $8,616 | $1,227 | 14.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 20 | $4,646 | $666.52 | 14.3% |
About Dr. Leonard Calabrese, DO
Dr. Leonard Calabrese, DO is a Rheumatology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467415265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leonard Calabrese, DO has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $255,559 received in 2024. These payments were reported across 1,647 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Calabrese has provided services to 146 Medicare beneficiaries, totaling 175 services with total Medicare billing of $9,004. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Cleveland, OH
- Active Since 04/11/2006
- Last Updated 01/28/2008
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1467415265
Products in Payments
- KEVZARA (Biological) $226,334
- SAPHNELO (Biological) $203,657
- KRYSTEXXA (Biological) $80,730
- Tavneos (Drug) $72,153
- KEVZARA (Drug) $71,944
- KEVZARA SARILUMAB INJECTION (Biological) $53,785
- SIMPONI ARIA (Biological) $45,868
- Actemra (Biological) $42,315
- COSENTYX (Biological) $42,069
- STELARA (Biological) $33,257
- ORENCIA (Biological) $29,559
- Bimzelx (Biological) $25,582
- TREMFYA (Drug) $23,871
- Otezla (Drug) $20,941
- RINVOQ (Drug) $19,500
- SHINGRIX (Biological) $19,322
- EVUSHELD (Drug) $17,062
- KRYSTEXXA (Drug) $16,033
- Sotyktu (Drug) $15,750
- Humira (Biological) $14,221
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Cleveland
Muhammad Khan, Md, MD
Rheumatology — Payments: $676,848
Rheumatology $676,848
Kristin Highland, M.d, M.D
Rheumatology — Payments: $630,614
Rheumatology $630,614
Chad Deal, Md, MD
Rheumatology — Payments: $525,018
Rheumatology $525,018
M Elaine Husni, M.d, M.D
Rheumatology — Payments: $301,718
Rheumatology $301,718
Brian Mandell, M.d, M.D
Rheumatology — Payments: $185,593
Rheumatology $185,593
Bruce Long, M.d, M.D
Rheumatology — Payments: $137,023
Rheumatology $137,023